AveXis Inc (AVXS) Receives Consensus Rating of “Buy” from Analysts

AveXis Inc (NASDAQ:AVXS) has received a consensus recommendation of “Buy” from the twenty analysts that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and thirteen have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $110.56.

A number of research analysts have weighed in on the company. Royal Bank of Canada reaffirmed a “hold” rating and set a $92.00 target price on shares of AveXis in a report on Thursday, November 2nd. Canaccord Genuity assumed coverage on AveXis in a report on Thursday, October 26th. They set a “hold” rating and a $110.00 target price for the company. Zacks Investment Research lowered AveXis from a “buy” rating to a “hold” rating in a report on Monday, October 30th. BidaskClub raised AveXis from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Finally, Citigroup lifted their target price on AveXis from $100.00 to $116.00 and gave the company a “buy” rating in a report on Monday, October 2nd.

AveXis (AVXS) traded down $2.66 during mid-day trading on Monday, reaching $102.08. The company’s stock had a trading volume of 837,600 shares, compared to its average volume of 502,150. The stock has a market cap of $3,264.15, a price-to-earnings ratio of -18.29 and a beta of 2.46. AveXis has a 1-year low of $50.56 and a 1-year high of $116.15.

AveXis (NASDAQ:AVXS) last posted its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.04). During the same quarter last year, the firm earned ($0.87) earnings per share. sell-side analysts predict that AveXis will post -6.23 earnings per share for the current fiscal year.

In other news, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $101.26, for a total transaction of $180,242.80. Following the completion of the transaction, the vice president now owns 1,780 shares of the company’s stock, valued at $180,242.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $101.23, for a total value of $1,518,450.00. Following the transaction, the insider now directly owns 1,841,019 shares of the company’s stock, valued at approximately $186,366,353.37. The disclosure for this sale can be found here. Insiders have sold 52,340 shares of company stock valued at $5,318,845 in the last three months. 18.60% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in the stock. California Public Employees Retirement System bought a new stake in AveXis in the 3rd quarter worth approximately $570,000. Cubist Systematic Strategies LLC lifted its position in AveXis by 688.6% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after buying an additional 1,577 shares during the last quarter. Highbridge Capital Management LLC bought a new stake in AveXis in the 3rd quarter worth approximately $967,000. Perceptive Advisors LLC lifted its position in AveXis by 147.5% in the 3rd quarter. Perceptive Advisors LLC now owns 671,181 shares of the company’s stock worth $64,923,000 after buying an additional 400,000 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in AveXis by 52.2% in the 3rd quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock worth $99,363,000 after buying an additional 352,456 shares during the last quarter. Institutional investors own 92.88% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://baseballnewssource.com/markets/avexis-inc-avxs-receives-consensus-rating-of-buy-from-analysts/1818573.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.